A Phase 4 interventional study of valsartan and amlodipine and valsartan and amlodipine in Hypertension, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-27.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 28th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2008, is one of 67 in phase 4, and was the 91st registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 728 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 51st largest by enrollment of the 222 interventional ones that give a count, is one of 25 that started in 2008, is one of 67 in phase 4, and was the 135th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy, other than Valsartan
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
Drug: valsartan and amlodipine
Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
Drug: valsartan and amlodipine
Drug pages: Valsartan · Amlodipine
Drug pages: Valsartan · Amlodipine
Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)
Time frame: Baseline and Week 4
Percentage of Patients Achieving the Blood Pressure (BP) Goal of < 140/90 mmHg at Weeks 2,4,8 and 12
Time frame: Weeks 2, 4, 8 and 12
Change From Baseline to Week 4 in Mean Sitting Diastolic Blood Pressure (MSDBP)
Time frame: Baseline and Week 4
Change From Baseline to Weeks 2, 8 and 12 in MSSBP
Time frame: Baseline and Weeks 2, 8 and 12
Change From Baseline to Weeks 2, 8 and 12 in MSDBP
Time frame: Baseline and Weeks 2, 8 and 12
Percentage of Patients Achieving BP Goal of MSSBP < 140mmHg at Weeks 2, 4, 8 and 12
Time frame: Weeks 2, 4, 8 and 12
| Milestone | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Started | 369 | 359 |
| Completed | 336 | 322 |
| Not completed | 33 | 37 |
| Withdrew: Adverse event | 9 | 19 |
| Withdrew: Unsatisfactory therapeutic effect | 2 | 0 |
| Withdrew: Protocol deviation(s) | 8 | 6 |
| Withdrew: Withdrawal by subject | 10 | 9 |
| Withdrew: Lost to follow-up | 4 | 3 |
| mmHg | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Baseline MSSBP | 163.9 ± 11.85 | 163.3 ± 11.40 |
| Week 4 MSSBP | 140.9 ± 14.61 | 144.4 ± 14.21 |
| Change From Baseline to Week 4 in MSSBP | -23.0 ± 14.60 | -18.9 ± 13.92 |
| Percentage of Patients | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Week 2 | 25.1 | 25.8 |
| Week 4 | 43.7 | 31.1 |
| Week 8 | 61.7 | 46.2 |
| Week 12 | 59.8 | 50.7 |
| mmHg | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Baseline MSDBP | 95.5 ± 11.19 | 95.0 ± 10.33 |
| Week 4 MSDBP | 84.8 ± 11.47 | 86.2 ± 9.6 |
| Change From Baseline to Week 4 in MSDBP | -10.7 ± 9.39 | -8.8 ± 9.08 |
| mmHg | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Baseline MSSBP | 163.9 ± 11.85 | 163.3 ± 11.40 |
| Week 2 MSSBP | 147.0 ± 14.93 | 146.0 ± 14.80 |
| Change From Baseline to Week 2 in MSSBP | -16.9 ± 13.94 | -17.3 ± 13.80 |
| Week 8 MSSBP | 136.0 ± 15.27 | 140.5 ± 15.91 |
| Change From Baseline to Week 8 in MSSBP | -27.9 ± 16.08 | -22.8 ± 16.15 |
| Week 12 MSSBP | 135.7 ± 14.97 | 139.2 ± 15.63 |
| Change From Baseline to Week 12 in MSSBP | -28.1 ± 16.59 | -24.1 ± 16.07 |
| mmHg | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Baseline MSDBP | 95.5 ± 11.19 | 95.0 ± 10.33 |
| Week 2 MSDBP | 88.2 ± 10.93 | 87.1 ± 10.38 |
| Change From Baseline to Week 2 in MSDBP | -7.3 ± 8.51 | -7.9 ± 9.66 |
| Week 8 MSDBP | 81.6 ± 11.15 | 84.0 ± 11.39 |
| Change From Baseline to Week 8 in MSDBP | -13.9 ± 9.97 | -11.0 ± 10.33 |
| Week 12 MSDBP | 81.5 ± 10.62 | 83.8 ± 10.61 |
| Change From Baseline to Week 12 in MSDBP | -14.0 ± 10.41 | -11.2 ± 10.48 |
| Percentage of Patients | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Week 2 | 31.1 | 32.5 |
| Week 4 | 49.2 | 37.5 |
| Week 8 | 66.1 | 49.6 |
| Week 12 | 62.8 | 55.7 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | — | 4/369 (1.1%) | 50/369 (13.6%) |
| Moderate Treatment Regimen (5/160 mg) | — | 10/359 (2.8%) | 29/359 (8.1%) |
| Event | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Angina pectorisCardiac disorders | 0/369 | 2/359 |
| Myocardial infarctionCardiac disorders | 0/369 | 2/359 |
| Abdominal painGastrointestinal disorders | 0/369 | 2/359 |
| Cardiac arrestCardiac disorders | 0/369 | 1/359 |
| Cardiac failure congestiveCardiac disorders | 0/369 | 1/359 |
| PalpitationsCardiac disorders | 0/369 | 1/359 |
| TachycardiaCardiac disorders | 0/369 | 1/359 |
| Small intestinal obstructionGastrointestinal disorders | 0/369 | 1/359 |
| Gait disturbanceGeneral disorders | 0/369 | 1/359 |
| Non-cardiac chest painGeneral disorders | 0/369 | 1/359 |
| Event | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) |
|---|---|---|
| Oedema peripheralGeneral disorders | 32/369 | 16/359 |
| DizzinessNervous system disorders | 19/369 | 14/359 |
| Age, Customized(participants) | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) | Total |
|---|---|---|---|
| < 65 years | 302 | 292 | 594 |
| >=65 years | 64 | 65 | 129 |
| Age, Continuous(years) | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) | Total |
|---|---|---|---|
| Mean | 54.4 ± 10.98 | 55.0 ± 10.98 | 54.7 ± 10.98 |
| Sex: Female, Male(Participants) | Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | Moderate Treatment Regimen (5/160 mg) | Total |
|---|---|---|---|
| Female | 157 | 157 | 314 |
| Male | 209 | 200 | 409 |
The record gives a start of Mar 2008 and a primary completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine